Personal Details (July, 2017)
- born September 19th 1965 in Berlin, Germany
- married, 1 son
- contact: Charité Campus CVK, Division of Cardiology and Metabolism, Dept of
Cardiology, Augustenburger Platz 1, D-13353 Berlin, Germany
- Email: s.anker@cachexia.de;
- Tel. mob: +49-177-45 90 950

---

Stefan D. Anker is Professor of (Tissue)Homeostasis in Cardiology & Metabolism (W3) at Charité Berlin (from June 2017). Dr. Anker studied medicine at Charité Berlin and completed his clinical training in Germany and the UK. He obtained his M.D. from Charité Medical School, Berlin, Germany (1993), and his Ph.D. (1998) at National Heart & Lung Institute of Imperial College London. He was Professor of Cardiology & Cachexia Research (W2) at Charité (2002-14), and Professor of Innovative Clinical Trials (W3) in Göttingen (2014-17).

Dr. Anker has authored more than 750 original papers, reviews, and editorials that are well cited (total citations: >49,000, h-index: 107, papers with ≥ 200 citations: 59; source: Scopus, 4th July, 2017). For his work Dr. Anker has won several prizes, and obtained a number of fellowships and grants, including 2 from NIH (WARCEF trial), 2 EU-FP7 & 2 IMI/Horizon2020 grants. He was co-ordinator for “SICA-HF” study (EU-FP7).

Dr. Anker is Vice President of the European Society of Cardiology (ESC, 2016-18), serving on the ESC board since 2012. Dr. Anker serves in the board of the Heart Failure Association (HFA) of the ESC since 2006; he was HFA President (2012-14), and currently chairs the HFA committee on regulatory affairs. He is founding Editor-in-Chief of the first open access heart failure journal ESC Heart Failure. Dr. Anker serves on the editorial boards of 4 scientific journals (including European Heart Journal and European Journal of Heart Failure), and he worked in several ESC Guideline task forces.
Dr. Anker is the founding president of the International Society on Sarcopenia, Cachexia and Wasting Disorders (SCWD – see www.cachexia.org). Dr. Anker is founding Editor-in-Chief of the Journal of Cachexia, Sarcopenia and Muscle (JCSM, 2016-IF: 9.70, see www.jcsm.info).
Dr. Anker was and is member of >30 international clinical trial steering committees, chairing or co-chairing several currently (FAIR-HF2, RESHAPE-HF2, EMPEROR-HFpEF, Fair-HFpEF) as well as in the past (incl. FAIR-HF, TIM-HF, AUGMENT-HF, IMPULSE-HF, and BACH). He served in a number of DMC’s (chairing 4) and end-point committees (chairing 4).

Best Papers

1. Anker SD, Ponikowski P, Varney S, et al. Wasting as independent risk factor of survival in chronic heart failure. Lancet 1997;349:1050-3.
2. Anker SD, Chua TP, Swan JW, et al. Hormonal changes and catabolic/anabolic imbalance in chronic heart failure: The importance for cardiac cachexia. Circulation 1997;96:526-34.
3. Niebauer J, Volk H-D, Kemp M, et al & Anker SD. Endotoxin and immune activation in chronic heart failure: a prospective cohort study. Lancet 1999;353:1838-42.
4. Anker SD, Negassa A, Coats AJS, et al. Prognostic importance of weight loss in chronic heart and the effect of treatment with angiotensin-converting-enzyme inhibitors: an observational study. Lancet 2003;361:1077-83.
5. Anker SD, Comin Colet J, Filippatos G, et al. Ferric carboxymaltose in patients with heart failure and iron deficiency. N Engl J Med 2009;361:2436-48.
6. Maisel A, Mueller C, et al. & Anker SD. Mid-region pro-hormone markers for diagnosis and prognosis in acute dyspnea: results from the BACH (Biomarkers in Acute Heart Failure) trial. J Am Coll Cardiol 2010;55:2062-76.
7. Koehler F, Winkler S, Schieber M, et al. & Anker SD. Impact of Remote Telemedical Management on Mortality and Hospitalizations in Ambulatory Patients With Chronic Heart Failure: The Telemedical Interventional Monitoring in Heart Failure Study. Circulation 2011;123:1873-80.
8. Anker SD, Koehler F, Abraham WT. Telemedicine and remote patient management in heart failure. Lancet 2011; 378:731-9
9. Ponikowski P, et al. & Anker SD. Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency†. Eur Heart J. 2015;36,657–68.
10. Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2016;37(:2129-200.
11. Packer M, …, Anker SD, …., TRUE-AHF Investigators. Effect of Ularitide on Cardiovascular Mortality in Acute Heart Failure. N Engl J Med. 2017;376:1956-1964.
12. Von Haehling S, Ebner N, Dos Santos MR, Springer J, Anker SD. Muscle wasting and cachexia in heart failure: mechanisms and therapies. Nat Rev Cardiol. 2017;14:323-41.